by Lisa Nadal | Mar 16, 2023 | Past Events
Prof. Dr. Dario Neri (CEO and CSO), Dr. Covelli (CMO), Dr. Dakhel, Dr. De Luca, Dr. Cazzamalli, Dr. Galbiati, Dr. Puca, Sara Puglioli. Matilde Bocci, Giulia Rotta, Eleonora Prodi and Aureliano Zana will participate at the event. Moreover, the following abstracts have...by Lisa Nadal | Mar 16, 2023 | Past Events
Prof. Dario Neri (CEO and CSO), and Emanuele Puca (Investor Relations) will participate at the event to present Philogen and its programs to the financial community.by Lisa Nadal | Mar 16, 2023 | Past Events
Dr. Covelli (CMO), Dr. Elia, Dr. Ravenni, and Dr. Nadal will participate at the event in Rome. The dermato-oncology team from St. Gallen will give a presentation entitled “Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable...by last | Nov 13, 2022 | Past Events
Philogen attends the SITC Annual Meeting in November 2022. Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against...by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More detailsby last | Sep 28, 2022 | 2022, Past Events
Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...
Recent Comments